| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1080/03009740600601526 |
| P698 | PubMed publication ID | 16641040 |
| P2093 | author name string | Mok CC | |
| P2860 | cites work | Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 |
| Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke | Q28167141 | ||
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
| A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women | Q28218670 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines | Q29619614 | ||
| Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo | Q30700059 | ||
| Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein | Q31956558 | ||
| Factors associated with coronary artery calcification in young female patients with SLE. | Q33188178 | ||
| Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome | Q33337713 | ||
| Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome | Q33344042 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients | Q33357081 | ||
| Peripheral vascular disease in patients with systemic lupus erythematosus | Q33564222 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. | Q54710071 | ||
| Interleukin-6 gene polymorphism is an age-dependent risk factor for myocardial infarction in men | Q56999138 | ||
| C-Reactive Protein, Interleukin-6, and Soluble Adhesion Molecules as Predictors of Progressive Peripheral Atherosclerosis in the General Population | Q57403312 | ||
| The A-1087IL-10 allele is associated with cardiovascular disease in SLE | Q57537233 | ||
| Premature coronary-artery atherosclerosis in systemic lupus erythematosus | Q33974685 | ||
| An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus | Q34063484 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q34272627 | ||
| Inflammatory markers and the risk of coronary heart disease in men and women | Q34376967 | ||
| Atherogenic autoantigen: oxidized LDL complexes with beta2-glycoprotein I. | Q35085895 | ||
| Cardiovascular complications in chronic kidney disease | Q35140917 | ||
| Autoantibody-mediated atherosclerosis | Q35172086 | ||
| Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus | Q35552164 | ||
| Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus | Q35552185 | ||
| Inflammatory response and the endothelium. | Q35928642 | ||
| CD4+ regulatory T cells: mechanisms of induction and effector function. | Q36281207 | ||
| Tumor necrosis factor-alpha, biologic agents and cardiovascular risk | Q36283524 | ||
| Accelerated atherosclerosis in autoimmune rheumatic diseases | Q36318870 | ||
| Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein | Q37358421 | ||
| Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups | Q40406427 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. | Q40461525 | ||
| Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study | Q40536982 | ||
| Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus | Q40537191 | ||
| Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus | Q41608189 | ||
| Vascular stiffness in women with systemic lupus erythematosus | Q43576508 | ||
| The bimodal mortality pattern of systemic lupus erythematosus | Q43703475 | ||
| Risk factors for cardiovascular disease in systemic lupus erythematosus | Q43767819 | ||
| Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease | Q43788592 | ||
| Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. | Q43848180 | ||
| Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators | Q43988923 | ||
| Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial | Q44238497 | ||
| Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease | Q44244036 | ||
| Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis | Q44261800 | ||
| Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus | Q44586795 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study | Q44652580 | ||
| Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations | Q45217508 | ||
| Arterial stiffness in chronic inflammatory diseases | Q46505839 | ||
| The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial | Q46557882 | ||
| The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort | Q46561334 | ||
| Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups | Q46660881 | ||
| Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study | Q46829594 | ||
| Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events | Q46968374 | ||
| Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes | Q48001590 | ||
| Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. | Q50781571 | ||
| Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. | Q51578946 | ||
| Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus. | Q51843253 | ||
| Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. | Q51957611 | ||
| Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. | Q52893152 | ||
| Usefulness of helical computed tomography in detection of mitral annular calcification as a marker of coronary artery disease. | Q53584017 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| thromboembolism | Q891391 | ||
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 85-95 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | Scandinavian Journal of Rheumatology | Q15767622 |
| P1476 | title | Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus | |
| P478 | volume | 35 |
| Q51129973 | Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus. |
| Q37371383 | Beyond immunosuppression - challenges in the clinical management of lupus nephritis |
| Q37642830 | Current management of antiphospholipid syndrome-related thrombosis |
| Q50228698 | Effect of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus. |
| Q51194691 | Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial. |
| Q36634248 | Emerging drug therapies for systemic lupus erythematosus |
| Q48891739 | Health-related quality of life in systemic lupus erythematosus and its association with disease and work disability. |
| Q34506731 | Metabolic alterations and increased liver mTOR expression precede the development of autoimmune disease in a murine model of lupus erythematosus |
| Q43173649 | Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus |
| Q37168035 | New developments in lupus-associated antiphospholipid syndrome |
| Q36008969 | Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus: a cohort study |
| Q51648740 | Reproductive health in women with systemic lupus erythematosus compared to population controls. |
| Q47131684 | Role of vitamin D deficiency in systemic lupus erythematosus incidence and aggravation |
| Q37255201 | Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies |
| Q57216480 | Subclinical carotid atherosclerosis in a patient with systemic lupus erythematosus |
| Q28072610 | The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus |
| Q50676326 | The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients. |
| Q36821493 | The role of preventive cardiology in systemic lupus erythematosus |
| Q51104155 | Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. |
| Q37690745 | Update on emerging drug therapies for systemic lupus erythematosus |
| Q43184257 | Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus |
| Q38103285 | Vitamin D and systemic lupus erythematosus: an update |
| Q37896358 | Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis |
Search more.